LAVAL, QC, April 14 /PRNewswire-FirstCall/ - Neptune Technologies & Bioressources Inc. ("Neptune") (NASDAQ.NEPT - TSX.V.NTB) provides guidance for the expected financial results of the fiscal 2009 third quarter and nine-month period ended February 28, 2009. These results represent the year-end results for its fiscal year 2009 now ending on February, 28.
Neptune expects total revenues for the three-month period ended February 28, 2009 in the range of $3,400,000 to $3,800,000 compared to $2,875,000 for the third quarter ended February 29, 2008 representing an increase of 18% to 32%.
Total revenues for the nine-month period ended February 28, 2009 are expected to be in the range of $8,200,000 to $8,600,000 compared to $7,130,000 for the nine-month period ended February 29, 2008. This revenue increase represents between 15% to 21% growth in the nine-month period ended February 28, 2009 compared to the nine-month period ended February 29, 2008.
Neptune is currently expanding its in-house production capacity to be completed, as planned, before summer 2009 while the Company continues to expand its customer base worldwide. Neptune expects revenue growth will be driven by repeat demand from existing customers and incoming demand from new customers from North America, Europe and Asia.
The world retail nutraceutical market represents more than $50 billion in annual sales and the European market, newly accessible to Neptune, accounts for more than one-third of this market with sales beyond $15 billion with cholesterol, heart health and mental health having a major impact.(1)
The Company is preparing for the projected incoming demand from Europe following NKO(R) Novel Food approval. The Company believes that several years of pre-marketing activities have resulted in substantial marketing visibility and recognition in Europe.
In that perspective, the Company is negotiating strategic alliances for high scale production wit
|SOURCE NEPTUNE TECHNOLOGIES & BIORESSOURCES INC.|
Copyright©2009 PR Newswire.
All rights reserved